Are GSK shares a bargain after falling 11%?

GSK shares have taken a hit in recent weeks due to Zantac uncertainty. Here, Edward Sheldon looks at whether they’re now cheap.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE: GSK) shares have taken a tumble recently. A month ago, they were trading for around 1,810p. Today however, the share price is sitting at 1,605p – roughly 11% lower.

Are the shares a bargain after this sharp drop? Let’s take a look.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Zantac uncertainty

For around two years now, there’s been some uncertainty surrounding GSK due to potential litigation related to Zantac – a heartburn drug that was originally marketed by Glaxo Holdings. It was withdrawn from shelves in 2019 after being linked to cancer.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

This uncertainty has come back into focus in recent weeks after a Delaware judge allowed more than 70,000 Zantac lawsuits to go forward, ruling that expert witnesses can testify in court that the drug may have caused cancer. These lawsuits could potentially cost the company a lot of money.

Now GSK – which has said that it will “vigorously defend itself” against all claims – has appealed the decision made by the Delaware judge. The FTSE 100 company believes that the scientific consensus is that there’s no consistent or reliable evidence that Zantac increases the risk of cancer.

However for now, the GSK share price remains well off its recent highs. Clearly, the uncertainty is spooking investors.

A bargain buy?

Given the high level of uncertainty related to Zantac, it’s hard to know if the shares are a bargain at current levels. However, my gut feeling is that they’re cheap.

With City analysts forecasting earnings per share of 177p for 2025, the forward-looking price-to-earnings (P/E) ratio is just 9.1. That’s well below the global sector average, which suggests that there’s some value on offer here. Rival AstraZeneca is currently trading on a P/E ratio of 17.

Of course, if GSK was to end up facing huge liabilities from Zantac litigation, the company’s profits could take a hit. In this scenario, the current earnings forecasts would become meaningless. And according to City AM, GSK hasb’t set aside any provision for liabilities beyond legal expenses to defend the litigation.

Potential liabilities

However, it’s worth pointing out that GSK peer Sanofi recently settled about 4,000 Zantac cases for $100m in private, according to Bloomberg. That would imply a payout of $25,000 per plaintiff. Assuming the same amount was paid for 70,000 lawsuits, GSK’s liability would come to around $1.75bn. That wouldn’t be the end of the world for the company, given that analysts are expecting a net profit of over $8bn this year.

One other thing worth mentioning is that analysts at Shore Capital believe that the worst-case scenario ($30bn in litigation costs) is currently being priced into the GSK share price. They have a price target of 2,200p for the stock at the moment. If they’re right, then today’s share price could definitely turn out to be a bargain. If the stock was to hit that level in the next 12 months, investors could be looking at total returns of over 40% once dividends are factored in (the yield is nearly 4% right now).

In light of this analysis from Shore Capital, I think the shares are probably worth considering today as a value play.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Value Shares

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »

Investing Articles

This FTSE AIM stock has £2.3bn in net cash, and a market cap of £2.4bn!

I love this FTSE AIM stock, but it really hasn’t delivered for me yet. The stock trades with crazily low…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 stocks that have been crushed and now offer a ton of value

Edward Sheldon has been scanning the market for stocks that offer value after the sell-off. Here are two shares he…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

2 beaten-down UK shares that now look really cheap

Looking for cheap shares to consider for the long term? These two British stocks offer a lot of value right…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

As stocks tank, is this a rare chance for ISA investors to get rich?

Shares have collapsed globally and valuations are becoming, on paper at least, a lot more attractive. Dr James Fox explores…

Read more »

Investing Articles

Can Greggs shares offer shelter from Trump’s tariff chaos?

Greggs' shares have plummeted in recent months. But with very little exposure to the US or tariffs, could the stock…

Read more »

US Stock

Apple stock is close to 52-week lows. Should I snap it up now?

Jon Smith discusses the double-digit percentage fall in Apple stock last week and weighs up whether now's the time to…

Read more »